Edwards Lifesciences is an American medical equipment company specializing in artificial heart valves and hemodynamic monitoring. The Company is mostly known for a transcatheter aortic heart valve made of bovine tissue within a collapsible stainless-steel stent, deployed via catheter. The Edwards SAPIEN family of heart valves are delivered via a procedure called transcatheter aortic valve replacement. The valve is designed to replace a patient’s diseased native aortic valve without traditional open-heart surgery and while the heart continues to beat – avoiding the need to stop the patient’s heart and connect them to a heart-lung machine that temporarily takes over the function of the heart and the patient’s breathing during surgery.

The Company also manufactures products for vascular therapy along with hemodynamic monitoring devices for measuring cardiovascular performance during surgery and in the ICU. Hemodynamic monitoring is the measurement of blood circulation and cardiac function that allows clinicians to evaluate whether enough oxygen is being delivered to the organs and tissues. Among these is the Swan-Ganz catheter. Originally developed for patients with acute myocardial infarction, it is now used in anesthesia and critical care units. Healthcare providers use this monitoring to detect changes or problems in a patient’s health, which allows for more informed, immediate treatment decisions. To facilitate on-pump cardiac surgery procedures through smaller incisions, Edwards also offers a cardiac surgery product line comprising soft tissue retractors, venous and arterial cannulae, aortic occlusion, venting, and coronary sinus catheters, as well as reusable instruments for performing minimally invasive valvular procedures.

Show more
Irvine, US
Size (employees)
11,100 (est)
Edwards Lifesciences was founded in 1958 and is headquartered in Irvine, US
Report incorrect company information

Key People/Management at Edwards Lifesciences

Michael Mussallem

Michael Mussallem

Chairman and Chief Executive Officer
Donald Bobo

Donald Bobo

Corporate Vice President, Strategy & Corporate Development
Dirksen Lehman

Dirksen Lehman

Corporate Vice President, Public Affairs
Christine McCauley

Christine McCauley

Corporate Vice President, Human Resources
John McGrath

John McGrath

Corporate Vice President, Quality, Regulatory, Clinical
Joseph Nuzzolese

Joseph Nuzzolese

Corporate Vice President, Global Supply Chain
Show more

Edwards Lifesciences Office Locations

Edwards Lifesciences has an office in Irvine
Irvine, US (HQ)
1 Edwards Way
Show all (1)
Report incorrect company information

Edwards Lifesciences Financials and Metrics

Edwards Lifesciences Financials

Edwards Lifesciences's revenue was reported to be $2.96 b in FY, 2016 which is a 18.8% increase from the previous period.

Revenue (FY, 2016)

3 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

2.2 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

569.5 m

Market capitalization (18-Apr-2018)

30.1 b

Cash (31-Dec-2016)

930.1 m


30 b
Edwards Lifesciences's current market capitalization is $30.1 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


2 b2.3 b2.5 b3 b

Revenue growth, %


Cost of goods sold

522.4 m625.6 m617.2 m797.4 m

Gross profit

1.5 b1.7 b1.9 b2.2 b
USDFY, 2013FY, 2014FY, 2015FY, 2016


420.4 m653.8 m718.4 m930.1 m

Accounts Receivable

302.5 m288 m28.7 m365.5 m


308.9 m296.8 m339.9 m396.6 m

Current Assets

1.7 b2.3 b2 b2.2 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

391.7 m811.1 m494.9 m569.5 m

Depreciation and Amortization

68.7 m68.6 m65.8 m71.2 m


(44 m)(31 m)(68 m)(65.6 m)
USDY, 2016


42.6 x


56.8 x


267 k


0.3 x


0.2 x

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information

Edwards Lifesciences News and Updates

BRIEF-Boston Scientific says co prevails in UK Edwards Lifesciences Litigation​


Edwards Lifesciences buys VC-backed Harpoon for up to $250 mln

Edwards Lifesciences has acquired Harpoon Medical Inc, a provider of beating-heart repair for degenerative mitral regurgitation, for up to $250 million. Harpoon Medical was backed by Epidarex Capital.
Report incorrect company information